Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenvervimab - GC Biopharma

Next Previous
X
Search
Drug Profile

Lenvervimab - GC Biopharma

Alternative Names: GC-1102; GC-5103; Hepabig; HepaBig Gene; Recombinant Hepatitis B Human Immunoglobulin - Green-Cross

Latest Information Update: 04 Mar 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Green Cross
  • Developer GC Biopharma
  • Class Antivirals; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Immunostimulants; Viral antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis B
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Hepatitis B

Most Recent Events

  • 18 Jan 2023 Phase-III clinical trials in Hepatitis B (prevention) in South Korea (IV) (GC Pharma pipeline, March 2021) (NCT05686759)
  • 17 Jan 2023 GC Biopharma plans a phase-III trial for Hepatitis B (Prevention) in January 2023 (IV, Infusion) (NCT05686759)
  • 29 Mar 2022 GC Pharma is now called GC Biopharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top